Aprea Therapeutics, Inc. (APRE) AI Stock Analysis
APRE AI stock analysis summary
AI ResearchAprea Therapeutics, Inc. is a clinical-stage biotechnology company focused on synthetic lethality-based cancer therapies. The company generated trailing twelve months revenue of $5,185 and posted net income of -$12.6M in FY2025. It held $41.2M in cash and short-term investments as of June 30, 2026, while its market capitalization stood at $7.4M.
- Market cap
- $7.4M
- Revenue (TTM)
- $5,185
- P/E
- —
- 1Y return
- -62.1% S&P 500 16.8%
- Avg. target
- $3.30 465.1% vs last close
Bull case
- Aprea holds $41.2M in cash and short-term investments as of June 30, 2026, compared to a market capitalization of $7.4M.
- The stock trades at a price-to-book ratio of 0.3x, below book equity of $38.5M.
- Analyst coverage features a mean price target of $3.30, which is 465.1% above the last close price of $0.58.
Bear case
- Trailing twelve months revenue totaled just $5,185, with an operating margin of -255025.5%.
- Free cash flow was negative at -$12.9M in FY2025 following a net loss of -$12.6M.
- Shareholder dilution has been substantial, with the 5-year share count increasing by 4866.4%.
What Aprea Therapeutics does
Aprea Therapeutics, Inc. is a biopharmaceutical firm dedicated to advancing synthetic lethality-based cancer therapeutics that target pathways and central targets involved in DNA damage response and cancer progression. Based in Doylestown, Pennsylvania, the company develops treatments that selectively target cancer cells while sparing healthy tissue. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor designed for the treatment of solid tumor indications.
Growth and profitability
Aprea Therapeutics reported revenue of $583,231 in FY2023, which increased by 157.6% to $1.5M in FY2024 before falling 81.0% to $285,759 in FY2025. From FY2023 to FY2025, the 2-year revenue CAGR was -30.0%. Net losses were -$14.3M in FY2023, -$13.0M in FY2024, and -$12.6M in FY2025, with R&D expenses reaching $7.0M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue growth declined 98.4% year-over-year, and trailing twelve months revenue was $5,185 with an operating margin of -255025.5%.
Balance sheet and cash flow
As of June 30, 2026, Aprea Therapeutics held $41.2M in cash and short-term investments, out of total assets of $42.3M, and shareholders' equity was $38.5M. The company had a current ratio of 13.55. Operating cash flow was -$12.9M and free cash flow was -$12.9M in FY2025. The company's 5-year share count change was 4866.4%.
Valuation and performance
Aprea Therapeutics trades at a price-to-book ratio of 0.3x and an EV-to-EBITDA ratio of 0.3x, compared to the median EV-to-EBITDA of 12.0x for its US-listed Healthcare peers. Its enterprise value was -$31.4M alongside a market cap of $7.4M. Over the trailing 1-year period, the stock declined 62.1%, while the S&P 500 (SPY) gained 16.8%. Over a 5-year span, the stock fell 99.4%, compared to an 83.0% return for the benchmark.
What analysts expect
Wall Street coverage includes 3 Strong Buy ratings, 1 Buy rating, and zero Hold or Sell ratings. The mean price target is $3.30, representing an upside of 465.1% compared to the last close of $0.58 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.36 on revenue of $0. The company has beaten EPS estimates in 3 of the last 4 quarters, and the next earnings date is November 11, 2026.
Key risks and what to watch
- The company's ongoing cash burn includes a FY2025 operating cash flow of -$12.9M against $41.2M in cash reserves.
- Substantial share count expansion of 4866.4% over 5 years presents ongoing dilution risk for common stockholders.
- Revenue dropped 81.0% in FY2025 to $285,759, with consensus expectations predicting $0 revenue for the fiscal years ending December 31, 2026 and December 31, 2027.
- The stock is down 62.1% over the past year and trades at $0.58, near its 52-week low of $0.55.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this APRE AI stock analysis
This page is an AI-written research summary of Aprea Therapeutics, Inc. (APRE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: APRE income statement, APRE balance sheet, APRE key metrics, APRE analyst forecast, APRE chart. See the APRE stock overview for the latest quote and news.
APRE AI stock analysis FAQ
What is Aprea Therapeutics' lead drug candidate?
Aprea's primary pipeline candidate is ATRN-119, an ATR inhibitor in clinical development targeting solid tumors through synthetic lethality mechanisms.
How much cash does Aprea Therapeutics have?
As of June 30, 2026, the company held $41.2M in cash and short-term investments, supporting a current ratio of 13.55.
Does APRE pay a dividend?
No, Aprea Therapeutics does not pay a dividend.
What is the consensus analyst target price for APRE?
The mean analyst price target is $3.30 across 4 positive ratings (3 Strong Buy, 1 Buy), which is 465.1% above the last closing price of $0.58 on October 16, 2026.